1. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuriesin vitroandin vivo
   Feng Liu et al, 2016 CrossRef
2. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
   Taylor Harding et al, 2019, Leukemia CrossRef
3. Stalled replication forks within heterochromatin require ATRX for protection
   M S Huh et al, 2016, Cell Death Dis CrossRef
4. Proteometabolomics of Melphalan Resistance in Multiple Myeloma
   David C. Koomen et al, 2019 CrossRef
5. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors
   Daniela Passeri et al, 2016, ChemMedChem CrossRef
6. Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma.
   Jerome Moreaux, 0 CrossRef
7. Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment
   Natalia Oddone et al, 2020, Front. Pharmacol. CrossRef
8. The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells
   Malka Cohen-Armon, 2020, Cancers CrossRef
9. PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
   Jie Wu et al, 2019, Mol Med Rep CrossRef
10. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
    Sara Ovejero et al, 2021 CrossRef
11. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.
    Jerome Moreaux, 0 CrossRef
12. PARP Inhibitors and Haematological Malignancies—Friend or Foe?
    Kathryn A. Skelding et al, 2021, Cancers CrossRef
13. Drug resistance in cancer: mechanisms and tackling strategies.
    Tanweer Haider et al, 2020, Pharmacol Rep CrossRef
14. The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
    Sara Ovejero et al, 2022, Front. Immunol. CrossRef
15. Targeting the DNA damage response in hematological malignancies
    Sanjay De Mel et al, 2024, Front. Oncol. CrossRef
16. Cross-conjugated vinylogous annulation of π-CF3-allyl Pd-complexes with 4-methyl-3-trifluoroacetyl-quinolones
    Chiliveru Priyanka et al, 2024, Chem. Commun. CrossRef
17. Expeditious synthesis of CF3-phenanthridones through a base-mediated cross-conjugated vinylogous benzannulation (VBA)
    Madhu Desagoni et al, 2024, Org. Biomol. Chem. CrossRef
18. Coexisting Thalassemia, Immune Thrombocytopenic Purpura, and Multiple Myeloma With Osteopenia: Complex Hematologic Case in an Adult Asian Male Patient
    Javier B Chambi-Torres et al, 2024 CrossRef